about
Targeted Therapy in Biliary Tract CancersAdvances in systemic therapy for advanced pancreatobiliary malignanciesProgression of targeted therapy in advanced cholangiocarcinomaDeregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential BiomarkersGemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trialsGemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in JapanPhase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.Long term responders to palliative chemotherapy for advanced biliary tract cancer.Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004)Routine histopathologic examination of two common surgical specimens-appendix and gallbladder: is it a waste of expertise and hospital resources?Tea consumption and the risk of biliary tract cancer: a systematic review and dose-response meta-analysis of observational studiesExpression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma.Inflammatory gene variants and the risk of biliary tract cancers and stones: a population-based study in ChinaComparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer.A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine.Tea consumption and risk of gallbladder cancer: A meta-analysis of epidemiological studies.Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic ReviewSurvival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer.TNF-alpha promotes lymphangiogenesis and lymphatic metastasis of gallbladder cancer through the ERK1/2/AP-1/VEGF-D pathway.Occurrence of pancreatic, biliary tract, and gallbladder cancers in Alaska Native people, 1973-2007Activation or suppression of the immune response mediators in biliary tract cancer (BTC) patients: a systematic review and meta-analysisPachymic acid inhibits tumorigenesis in gallbladder carcinoma cellsLymph node status after resection for gallbladder adenocarcinoma: prognostic implications of different nodal staging/scoring systems.The effects of buthionine sulfoximine on the proliferation and apoptosis of biliary tract cancer cells induced by cisplatin and gemcitabine.CCR7 mediates the TNF-α-induced lymphatic metastasis of gallbladder cancer through the "ERK1/2 - AP-1" and "JNK - AP-1" pathwaysA multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.Association of inflammatory and other immune markers with gallbladder cancer: Results from two independent case-control studies.Technical Aspects of Gallbladder Cancer SurgeryBiliary tract cancer incidence in the United States-Demographic and temporal variations by anatomic siteTargeted therapy for biliary tract cancer.Current status of chemotherapy for the treatment of advanced biliary tract cancer.Current therapy and future directions in biliary tract malignancies.Multidisciplinary collaboration in gallbladder carcinoma treatment: A case report and literature reviewTrend analysis and survival of primary gallbladder cancer in the United States: a 1973-2009 population-based study.Chemoradiation for unresectable gall bladder cancer: time to review historic nihilism?Gallbladder cancer: can newer insights improve the outcome?Adenocarcinoma of the ampulla of Vater: what treatment options are available?The role of polycomb repressive complexes in biliary tract cancer.Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer.
P2860
Q26798443-66DB6878-9862-4053-84CF-CCFAD1C61169Q26822703-65C753C8-F472-4D94-8909-F12F066EBBCDQ27016150-FA70168A-ABFA-427D-B919-279387D86E24Q28073195-3C06763E-7823-4FEC-9169-2D6C4330C374Q30318857-2948ABD3-5D52-4DF6-A9B5-69029A326062Q33390747-2A8ACA5F-6600-4670-92DE-AD37D26CF6D0Q33428545-2794CB83-C09C-476C-A36E-476C6DA1785DQ33593193-0A48F185-1A40-4074-ABDD-893E24F6EA7FQ33656703-4E1E9815-7225-43F5-B611-0D920AF69C52Q33690793-D87A4747-FCBA-4E5A-8584-6745FBD880E1Q33889317-8377671A-D52A-4F81-A4C3-106833F68983Q34180209-AB926C35-E68C-426B-BF92-0F1215B05713Q34443672-E2C39AF7-00ED-43C4-AEA2-50FB87A42A64Q35429914-6BFF649F-988C-44B4-BB35-4E0859178A2BQ35639659-C0AE57F0-E10E-4AAB-A0AE-BDC7D8A5F991Q35753736-374006AB-8B1F-4F3A-8C70-531540C4880EQ35871195-9F3D39F0-9625-472E-BEA4-61139EA48373Q35956259-BBACBAD8-FF92-470C-AFE4-53F14F3321E7Q35963258-94E51850-CAF6-4A6C-8BF7-59D8E0B745BDQ36159701-C15B9429-F212-4650-B354-E65C34A96DFDQ36260577-7B34C31C-3187-407A-9AEB-9FCFA64A9A4CQ36411636-3A73C39D-3E53-4A87-90EB-FD6B2AAF9EB9Q36416354-2D430FC1-29B1-4B90-8C9F-5008C993A96EQ36502644-C5583CB4-BB50-4593-AE58-A4659E9D170CQ36725058-54F4A287-1352-410D-A2BC-D92742DFC898Q36795363-A78CC075-55FF-42B3-BE80-3FB4ACD22638Q36893162-0ACE8537-8B13-4B69-8366-D18828DFA18DQ36924290-E3A2E1CE-FED2-4E2C-B4A2-1820DA6C2FF7Q37002851-E4D3F215-82D8-40D3-B733-95B85E4B6770Q37018448-5112E495-6CE0-4786-94B3-5591387FE231Q37132750-B6E58C3F-D94C-4F42-99A8-088536133EE7Q37138732-DD9252FF-2F58-49F9-8FFF-73E387C68C88Q37161293-4F08E187-35AC-4E96-82F5-61DE515F410AQ37288576-9AA21BD6-D6E9-4A22-9A08-1C617EB0F4D4Q37747311-577C7999-2C05-4EC2-8A03-D12734E2621CQ37783933-FFE3F04E-909B-4628-B8E6-8ECD0FEFB926Q37968331-3C03DE52-8DF6-4842-9D24-04248DE4142BQ38218306-CE4E0303-E4F1-4DFD-BA82-AF89B319565FQ38271374-F1E58963-C2CA-40BF-A631-347B83E50B0AQ38406050-82018C0B-0689-4155-9348-F89F0DC184C9
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Epidemiology of biliary tract cancers: an update.
@en
type
label
Epidemiology of biliary tract cancers: an update.
@en
prefLabel
Epidemiology of biliary tract cancers: an update.
@en
P2093
P2860
P50
P356
P1433
P1476
Epidemiology of biliary tract cancers: an update.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDN533
P577
2008-07-29T00:00:00Z